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Abstract
IMPORTANCE Pacemaker implantations as a treatment for atrioventricular (AV) block are increasing
worldwide. Prevention strategies for AV block are lacking because modifiable risk factors have not
yet been identified.
OBJECTIVE To identify risk factors for AV block in community-dwelling individuals.
DESIGN, SETTING, AND PARTICIPANTS In this population-based cohort study, data from theMini-
FinlandHealth Survey, conducted from January 1, 1978, to December 31, 1980,were used to examine
demographics, comorbidities, habits, and laboratory and electrocardiographic (ECG)measurements
as potential risk factors for incident AV block. Datawere ascertained during follow-up from January
1, 1987, through December 31, 2011, using a nationwide registry. A total of 6146 community-dwelling
individuals were included in the analysis performed from January 15 through April 3, 2018.
MAIN OUTCOMES ANDMEASURES Incidence of AV block (hospitalization for second- or third-
degree AV block).
RESULTS Among the 6146 participants (3449 [56.1%] women; mean [SD] age, 49.2 [12.9] years),
529 (8.6%) had ECG evidence of conduction disease and 58 (0.9%) experienced a hospitalization
with AV block. Older age (hazard ratio [HR] per 5-year increment, 1.34; 95% CI, 1.16-1.54; P < .001),
male sex (HR, 2.04; 95% CI, 1.19-3.45; P = .01), a history of myocardial infarction (HR, 3.54; 95% CI,
1.33-9.42; P = .01), and a history of congestive heart failure (HR, 3.33; 95% CI, 1.10-10.09; P = .03)
were each independently associated with AV block. Twomodifiable risk factors were also
independently associated with AV block. Every 10–mmHg increase in systolic blood pressure was
associated with a 22% higher risk (HR, 1.22; 95% CI, 1.10-1.34; P = .005), and every 20-mg/dL
increase in fasting glucose level was associated with a 22% higher risk (HR, 1.22; 95% CI, 1.08-1.35;
P = .001). Both risk factors remained statistically significant (HR for systolic blood pressure, 1.26
[95% CI, 1.06-1.49; P = .007]; HR for glucose level, 1.22 [95% CI, 1.04-1.43; P = .01]) after adjustment
for major adverse coronary events during the follow-up period. In population-attributable risk
assessment, an estimated 47% (95% CI, 8%-67%) of AV blocks may have been avoided if all
participants exhibited ideal blood pressure and 11% (95% CI, 2%-21%)may have been avoided if all
had a normal fasting glucose level.
CONCLUSIONS ANDRELEVANCE In this analysis of data from a population-based cohort study,
suboptimal blood pressure and fasting glucose level were associated with AV block. These results
suggest that a large proportion of AV blocks are assocated with these risk factors, even after
adjusting for other major adverse coronary events.
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Key Points
Question Are there readily modifiable
risk factors associated with the risk of
atrioventricular block?
Findings In this population-based
cohort study of 6146 community-
dwelling individuals, elevated blood
pressure and blood glucose levels were
associated with the development of
atrioventricular block. Population-
attributable risk calculations suggest
that elevated blood pressure and
glucose levels may be associated with
more than half of all cases of
atrioventricular block.
Meaning Optimizing blood pressure
and glucose level control may serve as
effective strategies to prevent clinically
relevant conduction disease and
pacemaker implantation.
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Introduction
Atrioventricular (AV) block is a common reason for pacemaker implantation, and the number of
pacemaker implantations is increasing.1 Atrioventricular block most commonly occurs in the absence
of significant cardiac disease and is generally attributed to idiopathic fibrosis of the conduction
system.2 By definition, the cause of that fibrosis remains unknown.
Less severe conduction abnormalities, such as PR prolongation3 and right4 and left5 bundle
branch block (BBB), are known to be associated with more severe forms of AV block requiring a
pacemaker. Although hypertension and higher fasting glucose level each predispose to these less
severe conduction abnormalities,6-8 no evidence to date, to our knowledge, suggests that such
modifiable risk factors might be connected to AV block itself.
Although pacemakers can usually provide adequate treatment of the symptoms of AV block, no
preventive or curative strategies are currently used in clinical practice. Although generally a low-risk
procedure, pacemaker implantation can involve a risk of serious complications, such as
pneumothorax, cardiac tamponade, and death.9 After implantation, patients require generator
changes, which carry a particularly high risk of infection and resultant endocarditis.10 Finally,
independent of these procedural complications, successful pacemaker therapy has been associated
with a worse prognosis.11-13
A better understanding of the conditions associated with severe AV conduction disease would
enable the development of prevention strategies, ideally avoiding the pacemaker-associated
complications and increased use of health care resources. No previous study, to our knowledge, has
reported the population-based characteristics associated with incident AV block. We therefore
sought to identify risk factors for AV block, with a particular emphasis on characteristics that are
known to bemodifiable.
Methods
StudyDesign
Participants were enrolled in theMini-Finland Health Survey from January 1, 1978, to December 31,
1980, as part of the Finnish Mobile Clinic Survey of the Social Insurance Institution, Helsinki, focusing
on the health status of the Finnish population. The detailed study protocol andmethods have been
previously published.14,15 Briefly, the original random sample was representative of the Finnish
population in 1978. The study included a health interview performed by a home-visiting trained nurse
followed by a health examination at the study clinic. A total of 8000 individuals (3637men and 4363
women) older than 30 years received an invitation to the survey, of whom7217 participated in health
examinations. Participants were excluded from the current study if they were deceased before
ascertainment of AV block occurred, if they hadmissing or poor electrocardiographic (ECG) data, if
they had second- or third-degree AV block or atrial or ventricular pacing on their baseline ECG, or if
data pertinent to any of the relevant covariates were missing, leaving 6146 participants for the
present study. TheMini-Finland Health Survey preceded the current legislation on ethics in medical
research in Finland.15 All participants were fully informed about the study and participated in the
study voluntarily, and the use of the information for medical research was explained to them.
Agreeing to participate in the baseline health examination was taken to indicate written informed
consent. The participants were free to unconditionally withdraw their consent at any time, in which
case their data were deleted. Record linkage of national health registers to the survey data was
approved by the register authorities (the Social Insurance Institution; the National Institute for Health
andWelfare, Helsinki; and Statistics Finland, Helsinki). Certification to analyze these deidentified
data was provided by the institutional review board of the University of California, San Francisco. This
study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
reporting guideline for cohort studies.
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Demographics andAnthropometricMeasurements
Age and sex were self-reported by study participants. Height was directly measured by study
personnel. Weight was measured using a calibrated scale with participants in light clothing, and 1 kg
was subtracted from the measured result. Blood pressure was measured using a manual
sphygmomanometer after 40minutes of completing questionnaires in a seated and comfortable
position. No eating, drinking, or smoking during that 40-minute period was allowed. Two blood
pressure measurements were obtained during a 1.5-minute interval, and the latter systolic and
diastolic readings were used for the purposes of the present study.
ECGMeasurements
A resting paper ECGwas recorded using the Olli 308 ECG device (KONE Oyj), with a paper speed of
50 mm/s and a calibration of 10 mm/mV. All ECGs were classified by 4 trained experts working in
pairs using revisedMinnesota coding as described previously.16,17 Conduction disorders such as
incomplete or complete right BBB, left anterior hemiblock, left posterior hemiblock, left BBB, and
interventricular conduction delay were manually confirmed for the purposes of the present study
according to revised criteria.18
LaboratoryMeasurements
Blood samples were obtained after 11 hours of fasting. Levels of serum cholesterol, high-density
lipoprotein cholesterol, triglycerides, and plasma glucose were measured in a single laboratory using
standard laboratory techniques.
Cardiovascular Comorbidities
Hypertension was defined as systolic blood pressure of greater than 140mmHg, diastolic blood
pressure of greater than 90mmHg, or a self-reported history of hypertension with the use of blood
pressure–loweringmedication. Diabeteswas defined as a fasting glucose level of at least 200mg/dL
in a singlemeasurement or at least 120mg/dL in 2 separatemeasurements (to convert tomillimoles
per liter, multiply by 0.0555) or use of a medication to lower glucose levels. All participants
underwent a standard 12-lead ECG and posterior-anterior and lateral chest radiography. Study nurses
specifically screened for each of the following diagnoses, which required confirmation by a study
physician. Angina pectoris was defined as a history of typical exercise-related chest pain relieved
within minutes of rest or with use of nitroglycerin substrates. Myocardial infarction (MI) was defined
as present given at least 1 of the following criteria: pathologic Q waves indicating transmural
infarction on study ECG; ECG findings consistent with a possible MI and previous hospitalization
because of MI with elevated cardiac enzyme levels; or typical history of MI and previous
hospitalization because of MI with elevated cardiac enzyme levels. Congestive heart failure (CHF)
was defined as present given at least 1 of the following criteria: documented history of treatment of
CHF symptoms, such as with diuretics, with a resultant positive response; signs of cardiac
decompensation on clinical examination; or significant enlargement of the heart on chest
radiographs (>650 cm3/m2 for men and >600 cm3/m2 for women).
Habits
Alcohol consumption and cigarette smoking were assessed using standard questionnaires. Current
or past smoking was defined as smoking of cigarettes regularly for a minimum of 1 year. Participants
were classified as current smokers, former smokers, or nonsmokers. Self-reported mean intake of
beer, wine, and liquor was used to calculate alcohol consumed on a regular basis as grams per week.
Follow-upData
Follow-up for hospitalization with second- or third-degree AV block, the primary end point for the
current study, began on January 1, 1987, when the use of the International Classification of Diseases,
Ninth Revision (ICD-9), was introduced in Finland. The first hospitalization with ICD-9 codes I44.1
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(second-degree AV block) or I44.2 (third-degree AV block) was used as the primary outcome. Major
adverse coronary events (MACEs) were defined as death or hospitalization due to acute coronary
syndrome (including unstable angina or MI) or a coronary revascularization procedure (International
Classification of Diseases, Eighth Revision, and ICD-9 codes 410 or 411; International Statistical
Classification of Diseases and Related Health Problems, Tenth Revision codes I20.0, I21, or I22; or
angioplasty or coronary artery bypass graft). Follow-up for MACEs was performed from the baseline
examination until December 31, 2011. Nationwide health registries were the source of all mortality
(Statistics Finland) and hospitalization (RegisterCare, Register for Health Care, and National Institute
for Health andWelfare) data. Thismethod has been previously validated and shown to capture 94%
of all events with no secular variation in accuracy.19
Statistical Analysis
Data were analyzed from January 15 through April 3, 2018. Continuous variables with a normal
distribution are presented as mean (SD) and were compared using unpaired 2-tailed t tests.
Nonnormally distributed continuous variables are presented as medians with interquartile range and
were compared using theMann-Whitney test. Categorical variables are presented as absolute
numbers and percentages and were compared using the χ2 test.
Cumulative incidence curves taking death as a competing risk into account were constructed to
illustrate the associations between covariates and incident AV block. Cox proportional hazards
regressionmodels were then used to calculate hazard ratios (HRs) and their 95% CIs for the
incidence of AV block. Inclusion of covariates in themultivariable model was first determined by
selecting those that exhibited 2-sided P < .10 in unadjusted analyses. With sex and age included as
fixed covariates in the multivariable model, inclusion of additional covariates was determined by
performing a stepwise backward selection process until all the other variables in themodel exhibited
P < .10. To test the reproducibility of the results, we performed a sensitivity analysis wherein we
adjusted for baseline demographics and all covariates with P < .10 to determine whether the same
covariates remained statistically significant.
Because evidence of conduction disease on baseline ECGwouldmore likely mediate rather than
confound relationships, we used a separate model including pertinent ECG data. We performed 2
secondary analyses. First, because intervening cardiovascular events may havemediated observed
associations, we performed an analysis adjusting for time-updated MACEs. Second, because the
pathophysiology of third-degree AV block may be different from that of second-degree AV block, we
performed an analysis restricted to third-degree AV block as the outcome.
The population-attributable risk of incident AV block was calculated for modifiable risk factors
found to have a statistically significant association with incident AV block using a semiparametric
approach.20,21 Specifically, the ratio of themean excess risk associated with the exposure of interest
to themean observed risk was calculated. Reference levels for systolic blood pressure (120mmHg)
and fasting glucose level (100mg/dL) were chosen according to recent guidelines,22,23 and 95% CIs
for these population-attributable risk estimateswere obtained using bootstrap resamplingwith 500
repetitions. To assess these population-attributable risks independent of the associationwith acute
coronary events, we performed a second analysis that omitted participants who had experienced
anMACE.
All models fulfilled proportional hazards assumptions. Data were analyzed using SPSS, version
23 (IBMCorp); Stata, version 15 (StataCorp); and R, version 3.5.2 (R Project for Statistical Computing).
A 2-tailed P < .05 was considered statistically significant.
Results
Themean (SD) age of the 6146 participants was 49.2 (12.9) years; 2697 (43.9%) weremen and 3449
(56.1%) were women. Electrocardiographic evidence of conduction disease was observed in 529
(8.6%) participants. The baseline characteristics according to the presence or absence of infranodal
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conduction disease are presented in Table 1. Characteristics of participants excluded from the study
(n = 1071) because of early death (before January 1, 1987) or missing data are listed in the eTable in
the Supplement.
Characteristics AssociatedWith Atrioventricular Block
During follow-up, 58 individuals (0.9%) developed AV block; among them, 40 (69.0%) had no
precedingMI or MACE. Two individuals (3.4%) of those with AV block died within 1 month of the
diagnosis, and a total of 6 (10.3%) died within 1 year of the diagnosis. The characteristics associated
with AV block are shown in Table 2. Older age (HR per 5-year increment, 1.47; 95% CI, 1.28-1.69;
P < .001), hypertension (HR, 2.38; 95% CI, 1.36-4.16; P = .002), angina pectoris (HR, 5.45; 95% CI,
2.15-13.81; P < .001), MI (HR, 8.80; 95%CI, 3.47-22.30; P < .001), CHF (HR, 12.18; 95%CI, 4.30-34.47;
P < .001), and higher levels of cholesterol (HR, 1.17; 95% CI, 1.06-1.27; P < .001), triglycerides (HR,
1.06; 95% CI, 1.04-1.10; P < .001), and fasting glucose (HR, 1.22; 95% CI, 1.13-1.32; P < .001) were each
associated with a greater incidence of AV block. After multivariable adjustment, older age (HR per
5-year increment, 1.34; 95% CI, 1.16-1.54; P < .001), male sex (HR, 2.04; 95% CI, 1.19-3.45; P = .01), a
higher systolic blood pressure (HR, 1.22; 95% CI, 1.10-1.34; P = .005), history of MI (HR, 3.54; 95% CI,
1.33-9.42; P = .01), history of CHF (HR, 3.33; 95%CI, 1.10-10.09; P = .03), and a higher fasting glucose
level (HR, 1.22; 95% CI, 1.08-1.35; P = .001) were each independently associated with incident AV
block (Table 2). In a sensitivity analysis including age, sex, and all other covariates exhibiting P < .10
in unadjusted analyses, systolic blood pressure (HR per 10–mmHg increase, 1.26; 95% CI, 1.06-1.49;
Table 1. Baseline Characteristics of ParticipantsWith Normal Conduction vs Conduction Abnormality
at Baseline
Characteristics
Study Groupa
P Valuec
Normal
Conduction
(n = 5617)
Any Conduction
Disease
(n = 529)b
Age, y 48.6 (12.7) 55.4 (13.7) <.001
Male sex, No. (%) 2394 (42.6) 303 (57.3) <.001
Height, cm 165.7 (9.3) 167.0 (10.1) .002
Weight, kg 70.9 (12.9) 74.7 (13.5) <.001
Body mass indexd 25.8 (4.0) 26.8 (4.3) <.001
Heart rate, bpm 67.6 (13.2) 66.0 (13.3) .007
Blood pressure, mm Hg
Systolic 140.8 (21.6) 147.1 (23.0) <.001
Diastolic 86.5 (11.3) 87.5 (11.6) .06
Hypertension, No. (%) 3148 (56.0) 362 (68.4) <.001
Diabetes, No. (%) 184 (3.3) 41 (7.8) <.001
Angina pectoris, No. (%) 176 (3.1) 68 (12.9) <.001
Myocardial infarction, No. (%) 114 (2.0) 46 (8.7) <.001
Congestive heart failure, No. (%) 85 (1.5) 38 (7.2) <.001
Blood pressure–lowering medication, No. (%) 664 (11.8) 127 (24.0) <.001
Alcohol consumption, median (IQR), g/wk 7.0 (0-49) 4.0 (0-36) .02
Smoking status, No. (%)
Nonsmoker 3180 (56.6) 293 (55.4)
.77Ex-smoker 1149 (20.5) 115 (21.7)
Current smoker 1288 (22.9) 121 (22.9)
Cholesterol level, mg/dL 267 (54) 271 (54) .25
High-density lipoprotein cholesterol level, mg/dL 66 (15) 62 (15) <.001
Triglyceride level, mg/dL 58 (35) 66 (77) <.001
Fasting glucose level, mg/dL 95 (22) 99 (25) .001
PR interval, ms 157.9 (21.1) 196.1 (33.1) <.001
QRS duration, ms 88.6 (10.6) 100.4 (18.8) <.001
Abbreviation: IQR, interquartile range.
SI conversion factors: To convert cholesterol to
millimoles per liter, multiply by 0.0259; glucose to
millimoles per liter, multiply by 0.0555; triglycerides to
millimoles per liter, multiply by 0.0113.
a Unless otherwise indicated, data are expressed as
mean (SD).
b Includes first-degree atrioventricular block (n = 331),
interventricular conduction delay (n = 53), left
anterior hemiblock (n = 45), left posterior hemiblock
(n = 50), incomplete (n = 16) or complete (n = 42)
right bundle branch block, and incomplete (n = 2) or
complete (n = 16) left bundle branch block.
c Calculated using unpaired 2-tailed t test, χ2 test, andMann-
Whitney test.
d Calculated as weight in kilograms divided by height
in meters squared.
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P = .007) and elevated glucose level (HR per 20-mg/dL increase, 1.22; 95% CI, 1.04-1.43; P = .01)
maintained a statistically significant association with a heightened risk of AV block.
After adjusting for time-updatedMACEs, neither a history of MI nor a history of CHFmaintained
a statistically significant association with incident AV block, and no other meaningful changes in
associations with other covariates were observed. When ECGmarkers of less severe conduction
disorders were examined, a longer PR interval (HR per 10-millisecond increase, 1.27; 95%CI, 1.18-1.34;
P < .001), longer QRS duration (HR per 10-millisecond increase, 1.45; 95% CI, 1.21-1.74; P < .001),
presence of right BBB (HR, 33.32; 95% CI, 14.17-78.37; P < .001), and presence of left BBB (HR, 23.16;
95%CI, 5.16-95.08; P < .001) were associatedwith incident AV block.When ECG-based evidence of
conduction disease was added to the multivariable model, older age (HR per 5-year increment, 1.19;
95% CI, 1.05-1.40; P = .02), a higher systolic blood pressure (HR, 1.22; 95% CI, 1.07-1.40; P = .002),
and an elevated fasting glucose level (HR, 1.20; 95% CI, 1.06-1.35; P = .003) maintained a statistically
significant association with incident AV block, along with a longer PR interval (HR, 1.23; 95% CI, 1.13-
1.34; P < .001), presence of right BBB (HR, 16.88; 95% CI, 6.79-41.98; P < .001), and presence of left
BBB (HR, 12.71; 95%CI, 3.00-53.88; P < .001) (Figure 1). Restricting the outcome to third-degree AV
block alone, higher systolic blood pressure (HR, 1.27; 95% CI, 1.08-1.47; P = .002), history of CHF
(HR, 3.97; 95% CI, 1.11-14.14; P = .03), higher fasting glucose level (HR, 1.20; 95% CI, 1.02-1.18;
P = .02), and the same ECG variables (HR, 1.17; 95% CI, 1.05-1.32; P = .006) were statistically
significant risk factors (Figure 1). The unadjusted cumulative risk of AV block, according to quartiles
of the 2 most directly modifiable risk factors, systolic blood pressure and fasting glucose level, is
illustrated in Figure 2.
Population-Attributable Risk
In estimation of population-attributable risk, elevated systolic blood pressure may have been
responsible for an estimated 47% (95%CI, 8%-67%) of all AV blocks, whereas elevated glucose level
may explain an estimated 11% (95% CI, 2%-21%) of all AV blocks (Figure 3). After excluding time-
updated coronary events, elevated systolic blood pressure continued to be statistically associated
Table 2. Unadjusted andMultivariable-Adjusted Risk Factors AssociatedWith Atrioventricular Block
Characteristic
Unadjusted Models Multivariable Modela
HR (95% CI) P Value HR (95% CI) P Value
Ageb 1.47 (1.28-1.69) <.001 1.34 (1.16-1.54) <.001
Male sex 1.44 (0.86-2.24) .16 2.04 (1.19-3.45) .01
Height 1.0 (0.97-1.02) .74 NA NA
Weight 1.01 (0.99-1.03) .17 NA NA
Body mass indexc 1.05 (0.99-1.12) .10 NA NA
Heart rate 1.00 (0.98-1.02) .86 NA NA
Blood pressured
Systolic 1.34 (1.22-1.48) <.001 1.22 (1.10-1.34) .005
Diastolic 1.40 (1.10-1.79) .003 NA NA
Hypertension 2.38 (1.36-4.16) .002 NA NA
Diabetes 4.44 (1.60-12.34) .004 NA NA
Angina pectoris 5.45 (2.15-13.81) <.001 NA NA
Myocardial infarction 8.80 (3.47-22.30) <.001 3.54 (1.33-9.42) .01
Congestive heart failure 12.18 (4.30-34.47) <.001 3.33 (1.10-10.09) .03
Blood pressure–lowering medication 1.95 (0.96-3.99) .07 NA NA
Smoking statuse 1.26 (0.75-2.10) .39 NA NA
Alcohol consumption 1.00 (1.00-1.01) .21 NA NA
Cholesterol levelf 1.17 (1.06-1.27) <.001 1.08 (0.98-1.20) .09
High-density lipoprotein levelf 0.77 (0.54-1.10) .14 NA NA
Triglyceride levelf 1.06 (1.04-1.10) <.001 NA NA
Fasting glucose levelf 1.22 (1.13-1.32) <.001 1.22 (1.08-1.35) .001
Abbreviations: NA, not applicable; HR, hazard ratio.
a Selection of covariates for multivariable models is
explained in the Statistical Analysis subsection of the
Methods section. Unless otherwise indicated, hazard
is interpreted as the presence (vs absence) of each
categorical variable or an increase of 1 unit of each
continuous variable.
b Interpreted as a hazard for every 5-year increase.
c Calculated as weight in kilograms divided by height
in meters squared.
d Interpreted as a hazard for every 10–mmHg increase.
e Dichotomized into current smokers and former
smokers vs nonsmokers.
f Interpreted as a hazard for every 20-mg/dL increase.
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with 40% (95% CI, 1%-69%) of AV blocks, and elevated glucose level was associated with
approximately 7% (95% CI, 1%-19%) of the outcomes observed.
Discussion
An elevated systolic blood pressure and an elevated fasting glucose level were each associated with
the development of AV block, even after adjusting for baseline and time-updated cardiovascular
Figure 1. Multivariable Adjusted Hazard Ratios (HRs) for Incident Atrioventricular (AV) Block
P Value
Lower Risk
of AV Block
Higher Risk
of AV BlockParticipant Characteristics
All AV Block (n = 58)
HR
(95% CI)
.02Agea 1.19 (1.05-1.40)
.051Male 1.72 (1.00-2.94)
.002Systolic blood pressureb 1.22 (1.07-1.40)
.09Myocardial infarction 2.46 (0.88-6.86)
.08Congestive heart failure 2.79 (0.90-8.72)
.07Cholesterol levelc 1.08 (1.00-1.20)
.003Fasting glucose levelc 1.20 (1.06-1.35)
<.001PR intervald 1.23 (1.13-1.34)
<.001Right bundle branch block 16.88 (6.79-41.98)
<.001Left bundle branch block 12.71 (3.00-53.88)
Third-degree AV Block (n = 40)
.06Agea 1.18 (0.95-1.40)
.25Male 1.47 (0.76-2.83)
.002Systolic blood pressureb 1.27 (1.08-1.47)
.03Congestive heart failure 3.97 (1.11-14.14)
.02Fasting glucose levelc 1.20 (1.02-1.18)
.006PR intervald 1.17 (1.05-1.32)
<.001Right bundle branch block 19.05 (6.31-57.50)
<.001Left bundle branch block 19.06 (4.42-82.30)
0.1 10 1001
HR (95% CI)
Incident AV block was defined as a hospitalization for
second- or third-degree AV block during the follow-up.
All covariates listed were included in multivariable
models. Unless otherwise indicated, hazard ratios
(HRs) were interpreted as a hazard for the presence
(vs absence) of each categorical variable or for the
increase of 1 unit of each continuous variable. To
convert cholesterol to millimoles per liter, multiply by
0.0259; glucose level to millimoles per liter, multiply
by 0.0555.
a Interpreted as a hazard for every 5-year increase.
b Interpreted as a hazard for every 10-mmHg increase.
c Interpreted as a hazard for every 20-mg/dL increase.
d Interpreted as a hazard for every 10-millisecond
increase.
Figure 2. Cumulative Incidence of Atrioventricular Block Taking Death as a Competing Risk Into Account
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Fasting glucose levelA Systolic blood pressureB
Quartile
First
Second
Third
Fourth
No. at risk
First quartile 
Second quartile 
Third quartile 
Fourth quartile 
1569 1365 12501465 1118 970
1507 1264 11361391 994 837
1532 1220 10681382 913 760
1534 1059 8781298 708 550
No. at risk
First quartile 
Second quartile 
Third quartile 
Fourth quartile 
1493 1385 13261443 1222 1110
1466 1298 12041390 1093 948
1573 1250 10771415 899 712
1610 975 7251288 519 346
Data are shown according to quartiles of fasting glucose level and systolic blood
pressure. The quartiles for systolic blood pressure were less than 126, 126 to 136, 137 to
152, and greater than 152mmHg. The quartiles for glucose level were less than 87.3, 87.3
to 93.1, 93.2 to 100.4, and greater than 100.4mg/dL (to convert to millimoles per liter,
multiply by 0.0555).
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disease as well as ECG evidence of conduction disease. These results suggest that elevated blood
pressure and blood glucose level may be associated with more than half of all cases of AV block.
Our study is, to our knowledge, the first community-based study to evaluate the association
between commonmodifiable cardiovascular risks and the incidence of AV block. Therefore, selection
bias that is commonly present in studies relying only on clinical information and experience with
patients presenting with cardiovascular disease is not relevant. Considering the severity of the
disease, we observed reasonably low 1-month and 1-yearmortality rates after a diagnosis of AV block.
Although ECG-basedmarkers of conduction disease have been associated with future pacemaker
implantation,3-5,24 associations between modifiable cardiovascular risks and second- and third-
degree AV block (and the associated pacemaker implantations) have not previously been assessed.
Not surprisingly, MI was associated with the incidence of AV block. Temporary AV block
associated with vagal effects and permanent AV block associated with structural damage of the
conduction system are both known to occur as a result of MI.2,25,26 We similarly found that structural
heart disease in the form of a history of MI or CHF was independently associated with AV block, but
most AV blocks (69.0%) occurred without a preceding history of MI or MACE.
Blood Pressure
The fact that a higher systolic blood pressure was associated with AV block even after adjusting for
baseline MI and time-updated MACE suggests a possible causal effect that may not be mediated by
infarction of cardiac tissue alone. Postmortem studies of individuals with AV block and no other
prevalent cardiovascular disease demonstrate fibrosis of the conduction system.2 This fibrosis, also
called Lev disease, is known to be age-related but is otherwise considered idiopathic.27,28
Hypertension and associated left ventricular hypertrophy are known to coexist with myocardial
fibrosis.29 It is intriguing to speculate whether elevated blood pressure might also lead to local
fibrosis infiltrating the AV conduction system.
Regardless of themechanism, if the association between elevated systolic blood pressure and
AV block was causal, our population-attributable risk calculations would suggest that almost half of
all AV blocks could be connected to an elevated systolic blood pressure. Studies examining lowering
of blood pressure to prevent conduction disease and AV block may be worthwhile, and perhaps at
the very least this new informationmight help to encourage individuals with hypertension to receive
and continue to use prescribed treatments.
Fasting Glucose Level
Fasting glucose level was associated with AV block in all models, and 11% of the AV blocks could be
attributed to it after adjusting for cardiovascular diseases and risks. Hyperglycemia, insulin
Figure 3. Multivariable-Adjusted Population-Attributable Risks of Systolic Blood Pressure and Fasting Glucose
Level for Atrioventricular (AV) Block
80
60
40
20
0
AV
 B
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, %
Censored at MACEAll Participants
Systolic Blood Pressure
Censored at MACEAll Participants
Fasting Glucose Level
The dark blue bars represent the population-
attributable risk for the listed covariates. The light blue
bars represent the population-attributable risk after
censoring participants from the model at the
occurrence of major adverse coronary events (MACEs)
(unstable angina pectoris, myocardial infarction,
angioplasty, and/or coronary artery bypass graft). All
models were adjusted for age, sex, history of
myocardial infarction, history of congestive heart
failure, and total cholesterol level. In addition, models
for systolic blood pressure were adjusted for fasting
glucose level, andmodels for fasting glucose level were
adjusted for systolic blood pressure. Error bars
represent 95% CIs.
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resistance, and type 2 diabetes are known predispositions to coronary disease andMI, offering a
possible explanation for the observed association.30,31 However, as with elevated systolic blood
pressure, the association between elevated glucose level and incident AV block persisted even after
adjusting for coronary events, suggesting that the true total effects may be substantially stronger
than what was observed. Diabetes also causes multiple changes in themetabolism of
cardiomyocytes, including increased lipotoxic effects due to aberrant use of fatty acids and increased
reactive oxygen species production, both of whichmay lead to cardiomyocyte injury and cell death
with resultant inflammation and fibrosis.32,33 Such processes may all predispose to
conduction disease.
Of note, a diagnosis of hypertension and a diagnosis of diabetes were each statistically
significantly associated with incident AV block; however, these associations were not retained in the
multivariable models. This finding was almost certainly due to collinearity with the raw
measurements of systolic blood pressure and blood glucose levels, which likely overwhelmed the
simpler, dichotomous risk factors because of their continuous nature (providing more power and
precision to detect a difference). However, given that these diagnoses andmeasurements in many
ways illustrate the same general pathophysiology, it would be inappropriate to conclude, for
example, that a diagnosis of hypertension or a diagnosis of diabetes was not an important risk factor
for AV block.
Strengths and Limitations
To our knowledge, this study is the largest to date to examine risk factors for incident AV block and
the only community-based study to be used for this purpose. Our study populationwas not limited to
individuals seekingmedical care, as is typical in medical record review studies or studies using
administrative databases. Particularly comprehensive baseline covariate ascertainment was
performed in a uniform fashion according to a prespecified protocol. This study also leverages the
hospital admission data registry in Finland, which captures all hospitalizations. Because clinically
relevant AV block would very likely result in hospitalization, we expect that outcome ascertainment
was particularly sensitive. Finally, follow-up extending to 32 years enabled us to collect a sufficiently
large number of outcomes to detect several statistically significant associations and to adjust for
important time-updated events.
One limitation of this study is that it was performed in a solely white population, and the
extrapolation of its results to other populations should be performed with caution. In addition, the
observational nature of our study does not allow us to draw any conclusions about the causal
relationship between the cardiovascular risks observed and incidence of AV block. Atrioventricular
block ascertainment for the study began in 1987, leaving a 7- to 9-year gap during which only data
regarding death and MACEs were available. Although this restriction might primarily reduce our
power to detect significant associations, risk factors for particularly more severe forms of conduction
disease might have beenmissed. The ICD codes do not differentiate betweenMobitz type I and II
blocks, and the pathophysiology and clinical relevance of these 2 forms of AV block can be very
different.34,35 However, our analysis of only those with third-degree AV block did not reveal any
meaningful differences. Temporary AV block is known to occur at the time of myocardial ischemia or
MI,2 andwe cannot exclude the possibility that some of the outcomes observedwere owing to that
phenomenon. However, analyses adjusting for time-updatedMACEs and population-attributable risk
calculations after censoring all patients with a MACE continued to demonstrate that an elevated
systolic blood pressure and blood glucose level were independently associated with AV block.
We acknowledge possible disagreement regarding the optimal approach to conducting
multivariable analyses to determine themost important risk factors for a given outcome. For
example, according to a recent set of guidelines, our select stepwise approachmay not always be
appropriate but is considered suitable in the absence of previous studies to identify the likely
covariates for inclusion.36 Given the relative dearth of research in this area, we believe the approach
used was most appropriate; furthermore, in a sensitivity analysis using broader inclusion of
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covariates, the associations for elevated systolic blood pressure and elevated glucose level remained
statistically significant. A next natural stepmight be to conduct studies specifically to construct and
test a risk prediction score and to provide evidence thatmight reveal mechanisms contributing to the
disease process and prevention strategies. Although such a step is beyond the scope of the current
study, our finding that readily accessible data may be identified as important to future AV block risk
mightmotivate even larger cohorts, consortia of cohorts, or planned prospective studies to institute
this next step.
Conclusions
Atrioventricular block is associated with multiple known cardiovascular risk factors and conditions.
In this study, the common, easily measured, andmodifiable risk factors of an elevated systolic blood
pressure and a higher fasting glucose level were independently associated with AV block. Taken
together, these 2 directly modifiable variables potentially explain more than half of all AV blocks in a
community-based population. Effective treatment of hypertension and maintenance of normal
blood glucose levels may be useful strategies in preventing AV block.
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SUPPLEMENT.
eTable. Characteristics of the Study Population and Individuals Excluded Due to Early Death (n = 854), Missing/
Poor Quality ECG (n = 200), or Other Missing Covariate (n = 17)
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